Advanced searches left 3/3
Search only database of 8 mil and more summaries

Company Makes Remdesivir

Summarized by PlexPage
Last Updated: 02 July 2021

* If you want to update the article please login/register

General | Latest Info

After a somewhat chaotic initial rollout by the US government, Gilead Sciences is now taking distribution of COVID-19 Drug Remdesivir into its own hands. Starting Thursday, Gilead will directly sell Remdesivir, branded as Veklury, to American hospitals, ending the five-month phase when the US Department of Health and Human Services was responsible for allocating it, company and HHS say. AmerisourceBergen will remain the sole US distributor through the end of the year. Gilead has been collecting revenue on drug since July at a wholesale acquisition cost of 3 120 for a typical five-day treatment course. That's when its US donation of about 1. 5 million doses run out. At that price, Wolfe Research analyst Tim Anderson projects Remdesivir peak sales in both 2020 and 2021 at just below 3 billion. Gilead itself expects to sell about 1 million to 1. 5 million courses this year, which roughly equates to 3. 5 billion in revenue. Remdesivir is one of only few drugs to show signs of benefits in COVID-19 during the early days of the pandemic. But just like the world Response To Virus, initial distribution of antiviral Drug was confusing under feds oversight. Some doses go directly to hospitals but not necessarily to those in greatest need, and some hospitals either didnt receive enough or were left empty-hand, NPR reported in May, weeks after Remdesivir won its Emergency Use Authorization from the FDA. Allocations improve later, but hhs' methods for earmarking doses remain a mystery. Meanwhile, Gilead quickly worked to ramp up supply, increasing internal manufacturing capacity and signing on contractors. Now, supplys exceeding market demand. At the end of June, HHS secured more than 500 000 treatment courses of Drug, which represent nearly all of Gileads yield through September. However, States and territories havent been accepting their full allocations, and only 32 % of the total amount was actually purchased by hospitals from July to September, HHS said Thursday, citing data from its Office of Assistant Secretary for Preparedness and Response. Now that Gileads is meeting real-time demand for drugs in the US, HHS and company decided its time for HHS to bow out and let company handle commercial sales directly to hospitals. Remdesivir distribution will now follow a plan that Gilead says closely reflects traditional model hospitals use to procure medicines. Big Biotech also says it will meet global demand starting this month, even in the event of another wave of COVID-19 infections. Remdesivir has shown it can cut recovery time for hospitalized patients by about 30 %, or four days, but its ability to slash death rates wasnt statistically significant in a clinical trial run by NIH. Besides, drugs benefit To moderately ill patients was debatable; studies show Drug, as 5-day treatment but not as a 10-day regimen, was better at helping moderate COVID-19 patients achieve clinical status improvement compared with standard therapy. In comparison, low-cost corticosteroids have shown they can save lives in critically ill patients.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Dive Brief:

Pfizer will produce vials of GILEAD's COVID-19 drug Remdesivir at its sprawling factory in McPherson, Kansas under a multi-year manufacturing agreement announced by the pharma giant Friday. Face with high demand for Remdesivir from countries around the world, GILEAD is working to quickly scale up production of the drug, which was shown in a US government-run study to hasten time to recovery among patients hospitalized with COVID-19. Supplies, however, are tight. From start to finish, making drug takes six months, even after GILEAD cut several months from its manufacturing timeline. The Agreement with the Trump administration, meanwhile, reserves for US 100 % of Remdesivir GILEAD produced in July, and 90 % in both August and September.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Dive Insight:

Steady tick, tick of counter for confirm COVID-19 cases worldwide pay no regard to news that as of the first week of July, US Department of Health and Human Services has bought out nearly the entire global supply of Remdesivir for upcoming months. Antiviral Drug is one of few supportive medications for COVID-19 patients, and represent a last glimmer of hope as clinical trials for its alternatives are discontinue. It is unsurprising, then, that the deal struck between HHS and Remdesivir manufacturer GILEAD Sciences, which secured 100 per cent of Gileads project production for July and 90 per cent for August and September, was met with fervent unease. Give the capricious nature of the pandemic, degree to which this deal might threaten global health responses over coming months remains unknown. According to Thomas Senderovitz, WHO lead Danish Medicines Agency, Denmark has enough supply of Remdesivir to make it through summer if the intake of patients is as it is now, though there is fear that challenge may arise if a second wave is to occur. However, what is certain is greater concern that unprecedented buyout signals unwillingness to cooperate with other countries. Calls have been made for the establishment of stronger frameworks that guarantee fair pricing for and access to key Medicines. Yet, deeper dive into the history of pharmaceutical giant GILEAD may provide insight as to how Remdesivir deal might be an unsuspecting candidate for executing the very results sought by critics. In early 2019, GILEAD was the face of an innovative new market model known to Health economists as the Netflix model. At its core, this model involves two agents: manufacturer and the payer. In exchange for some lump sum payment, manufacturer provides payers with unrestricted access to Drug, originally intended as treatment for hepatitis C, and both parties benefit payers negotiating reducing price for medication, while the manufacturer guarantees recovery of production costs. The terms of the Louisiana-GILEAD contract ensure accessibility and affordability of hepatitis C Drug, and Governor John Edwards is confident that this deal is a big step forward in the effort to eradicate hepatitis C in Louisiana. Meanwhile, until 2024, GILEAD will have a monopoly on hepatitis C treatment drugs across the state. When it comes to single-entity market structure in pharma, rules of microeconomic theory are distort. Monopolies are often blamed for drug price inflation, as a single player in control of market supply implies that competitive pricing schedules need not apply. Still, and perhaps counterintuitively, monopolistic market structures can derive benefits that instead lower drug prices and resolve health care inefficiencies, as evidence from the Louisiana-GILEAD contract. Monopsony, on other hand, invokes similar fear but for a different reason: it implies a single buyer has power to restrict product access to everyone else.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Sources

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summaries are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo

© All rights reserved
2021 made by Algoritmi Vision Inc.

If you believe that any of the summaries on our website lead to misinformation, don't hesitate to contact us. We will immediately review it and remove the summaries if necessary.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.